Yes, and in my view there's not many catalysts of significance in 2022 to keep the sp elevated should the market descend into turmoil. AIS and XP results? Well, they are only Phase 2 so I'm not sure how the market will respond to good results. Not enthusiastically I'm guessing or as much as we would like.
OTCs? Hardly anybody knows who or what Clinuvel is, let alone what the OTCs will be capable of doing when launched. If the marketing campaign is run on the cheap, then its going to take some time to get traction. I'm looking forward to Clinuvel finally getting the OTCs underway, but they've hinted they will start with a small production run so I'm not counting on it generating any major positive sp influence in 2022.
China news could be a driver this year, but other than that its really just down to solid, increasing earnings to propel the sp forward. I don't think we'll be seeing many promises made this year which I prefer, my frustration was palpable when next to no timelines were achieved last year. 2022 is the year they adhere to Captain Bligh's mantra: "First certainty, then talking about it"